Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy

Journal of Thoracic Oncology

Volumn 7, Issue 6, 2012, Pages 1041-1048

  Kelly, Karen ^a   Azzoli, Christopher G ^b   Zatloukal, Petr ^c   Albert, István ^d   Jiang, Peter Y Z ^e   Bodkin, David ^f   Pereira, José Rodrigues ^g   Juhász, Erzsébet ^h   Iannotti, Nicholas O ⁱ   Weems, Garry ^j   Koutsoukos, Tony ^j   Patel, Jyoti D ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Pulmonary Department   (Hungary)

^e Providence Regional Medical Center Everett   (United States)

^f Hematology/Oncology   (United States)

^g Hospital Dr Arnaldo de Vieira de Carvalho   (Brazil)

^h NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

ⁱ The Treasure Coast   (United States)

^j Allos Therapeutics Inc   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

antifolate; nonsmall cell lung cancer; pralatrexate; survival

Indexed keywords

CYANOCOBALAMIN; ERLOTINIB; FOLIC ACID; PLATINUM DERIVATIVE; PRALATREXATE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA;

EID: 84861336479     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824cc66c     Document Type: Article

References (21)

1. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
4. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
5. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
6. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
7. Schneider CP, Heigener D, Schott-von-Römer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008;3:1446-1453.
8. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
9. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
10. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 1998;42:313-318. (Pubitemid 28393849)
11. Toner LE, Vrhovac R, Smith EA, et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006;12(3 Pt 1):924-932. (Pubitemid 43259875)
12. DeGraw JI, Colwell WT, Piper JR, Sirotnak FM. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 1993;36:2228-2231. (Pubitemid 23241156)
13. Izbicka E, Diaz A, Streeper R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 2009;64:993-999.
14. Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44:1027-1035. (Pubitemid 36417003)
15. Krug LM, Ng KK, Kris MG, et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 2000;6:3493-3498.
16. Krug LM, Azzoli CG, Kris MG, et al. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003;9:2072-2078. (Pubitemid 36687627)
17. Pietanza M. EGFR mutations in men and cigarette smokers with lung adenocarcinoma. Abstract 10538. Presented at the ASCOAnnual Meeting, American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010.
18. OSI Pharmaceuticals, LLC, Genentech USA, Inc. Tarceva (erlotinib) tablets [Package Insert]. Available at: http://www.gene.com/gene/products/information/ pdf/tarceva-prescribing.pdf. Accessed January 5, 2012.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
20. Fleming TR Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis 2004;190:666-674. (Pubitemid 39049994)
21. Clark G, Cameron A, Das Gupta A. Clinical benefit of erlotinib in male smokers with squamous-cell NSCLC. J Clin Oncol 2006;24:7166.